Register to view the archived recording here.
Asuragen, microRNA Rx Subsidiary Awarded NIH Grants to Support Rx, Dx-Development
The grant issued to Asuragen will help the company identify miRNA biomarkers for colon cancer recurrence, while Mirna Therapeutics' grant will fund its efforts to develop prostate cancer drugs based on the small, non-coding RNAs.
New to GenomeWeb? Register here quickly.